BioSpace News Archive

AbbVie (NYSE: ABBV) today announced positive top-line results from U-EXCEL, a Phase 3 induction study, showing upadacitinib (45 mg once daily) achieved both primary endpoints of clinical remissiona,b and endoscopic responsec at week 12.

Mirus Bio, a leading provider of delivery solutions within Gamma Biosciences , today launched Trans IT-VirusGEN ® SELECT Transfection Kits for large-scale viral vector production for cell and gene therapy applications.

Cerapedics Inc. announced today the completion of enrollment of the ASPIRE study, a pivotal U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) study.

Regulus Therapeutics Inc. (Nasdaq: RGLS), today announced the completion of enrollment in the Phase 2 HERA clinical study evaluating lademirsen (RG-012) for the treatment of adult patients with Alport Syndrome under the Company’s Collaboration and License Agreement with Sanofi.

Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to its novel investigational therapy, BI 1015550, for the treatment of idiopathic pulmonary fibrosis (IPF).

Ardelyx, Inc. announced that it has entered into a debt financing agreement with investment affiliates managed by SLR Capital Partners.

Artio Medical, Inc., a medical device company developing innovative products for the peripheral vascular, neurovascular, and cardiology markets, today announced the hiring of Dan Tamez as Senior Director of Nonclinical and Clinical Research and the engagement of Geoff Tansley, PhD as Senior R&D Consultant.

EMD Serono announced new real-world data from the MSBase Registry demonstrating MAVENCLAD® tablets had more favorable relapse outcomes and longer time to switch to another disease modifying therapy compared to the oral DMTs fingolimod, dimethyl fumarate and teriflunomide in relapsing multiple sclerosis patients.

Naveris, Inc., a leader in molecular diagnostics for viral cancers, today announced the presentation of significant new data at the plenary session of the ASTRO 2022 Multidisciplinary Head and Neck Cancers Symposium supporting the clinical value of its flagship diagnostic test, NavDx®.

BiomX Inc. announced that Jonathan Solomon, Chief Executive Officer of BiomX, will present at the 2022 Aegis Virtual Conference on February 24, 2022, the Chardan 4th Annual Microbiome Medicines Summit on March 1, 2022 and the Oppenheimer & Co.